/
Vaccine Update and Refresher for Immunizations: 2012 Vaccine Update and Refresher for Immunizations: 2012

Vaccine Update and Refresher for Immunizations: 2012 - PowerPoint Presentation

min-jolicoeur
min-jolicoeur . @min-jolicoeur
Follow
345 views
Uploaded On 2019-02-07

Vaccine Update and Refresher for Immunizations: 2012 - PPT Presentation

Krista D Capehart PharmD MSPharm AEC David G Bowyer R Ph Assistant Professors of Pharmacy Practice University of Charleston School of Pharmacy Objectives Determine the appropriate vaccine recommendations for a patient based on current immunization schedules ID: 750845

years 2011 immunization influenza 2011 years influenza immunization vaccine vaccination adults www dose pneumococcal give coverage org risk immunize

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Vaccine Update and Refresher for Immuniz..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Vaccine Update and Refresher for Immunizations: 2012

Krista D. Capehart, PharmD, MSPharm, AE-C

David G. Bowyer, R. Ph.

Assistant Professors of Pharmacy Practice

University of Charleston School of Pharmacy Slide2

Objectives

Determine the appropriate vaccine recommendations for a patient based on current immunization schedules.

Apply individual vaccine characteristics to identify anticipated vaccine adverse events.

Explain the Advisory Committee on Immunization Practices (ACIP) recommendations for vaccines pharmacists can administer in West Virginia.

Summarize critical information needed for the administration of influenza and pneumococcal.

Investigate information about the vaccines added to Title 15 Series 12 of the West Virginia Code for immunization rules.Slide3

Pharmacist Administered Immunizations in WV

HB 3056 passed in 2008 authorizing specially trained pharmacists in WV to administer influenza and pneumococcal polysaccharide

Additional vaccines could be added following joint rule-making with WV Board of Medicine, WV Board of Osteopathy, and WV Board of Medicine

Summer 2011 joint rule-making occurred and was approved by the 2012 Legislature

Pharmacists can now administer Hepatitis A, Hepatitis B, Tetanus, and Herpes Zoster in addition to influenza and pneumococcal vaccinesSlide4

Current Title 15 – Series12

Qualifications for pharmacists to administer immunizations:

Any person ≥ 18 years old

Registered with the Board of Pharmacy (BOP) to administer immunizations

Successfully complete immunization training course approved by the BOP

Maintain current certification to basic life-support

Complete 2 hours annually of continuing education related to immunizationsSlide5

Current Title 15 – Series12

Must have immunization questionnaire and consent form, notify patient’s primary care provider (PCP) within 30 days of administration

Report the administration to the WV Statewide Immunization Information (WVSII) database within 30 days of administration

Must have consent & questionnaire readily retrievable and maintained on file for not less than 5 years

Pharmacists can administer epinephrine and diphenhydramine to manage acute allergic reaction following CDC guidelines

Pharmacists must have readily retrievable emergency response plan as outlined by the CDC and a readily retrievable emergency kit to manage an acute allergic reaction to an immunization administeredSlide6

Pharmacists as Immunizers in WV

As of June 2012, 1663 pharmacists have completed the mandated training course and are registered with the West Virginia Board of Pharmacy as Immunizing Pharmacists.

This represents approximately 50% of the pharmacists practicing in WV.

T

his addition to the immunizing workforce increases the access to immunizations for the public.

Slide7

Updates to Title 15 – Series 12

Adds:

Hepatitis A

Hepatitis B

Herpes Zoster

Tetanus (follows CDC recommendations and permits tetanus-diphtheria (Td) or tetanus-diphtheria-pertussis (Tdap)

Pharmacists must report all adverse events to the Vaccine Adverse Events Reporting System (VAERS) and provide a copy to the BOP

(available at http://vaers.hhs.gov/index)Slide8

Case Study 1

A family comes in to the pharmacy. The mother is a 40yo WF with a 15yo WM and 19 WF children requests immunizations for herself and her family. After discussing with her what she needs, you determine that they all need TIV and her daughter needs Hep B.

What immunizations could the pharmacist currently provide for the family?Slide9

Advisory Committee on Immunization Practices (ACIP)Recommendations for Adult Influenza Immunizations

Vaccination recommended for all adults (including healthy adults 19-49 years without risk factors)

Live attenuated influenza vaccine – only approved for healthy non-pregnant people age 2-49 years

65 years and older can get standard-dose Trivalent inactivated influenza vaccine (TIV) or the high does TIV

Give 1 dose every year in the fall or winter

Begin vaccination as soon as vaccine is available and continue until supply is depleted

If 2 or more live virus vaccine are given – give same day or they must be separated by at least 28 days

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide10

Advisory Committee on Immunization Practices (ACIP)Recommendations for Adult Influenza Immunizations

Mild illness is not a contraindication

Contraindications:

Previous anaphylactic reaction to vaccine, components, or eggs

LAIV only: pregnancy, chronic pulmonary problems, cardiovascular (except hypertension), renal, hepatic, neurological/neuromuscular, hematologic, or metabolic disorders, immunosuppression

Precautions:

Moderate or severe acute illness

History of Guillain-Barre syndrome within 6 weeks of previous influenza

LAIV only: taking antivirals 48 hours before vaccination and avoid using antivirals for 14 days after vaccination

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide11

Estimates of Cumulative Influenza Vaccination Coverage for 2010-2011 Season

West Virginia 48%

United States 43%

Among those ≥ 18 years in US vaccination rate 40.4%

High risk group remains: elderly, young children, pregnant women, and people with chronic conditions

Healthy People 2020 target is:

80% for persons 6 months – 64 years

90% for those ≥ 65 years

Final state-level influenza vaccination coverage estimates for the 2010–11 season–United States, National Immunization Survey and Behavioral Risk Factor Surveillance System, August 2010 through May 2011 available at http://www.cdc.gov/flu/professionals/vaccination/coverage_1011estimates.htmSlide12

Influenza Activity U.S. 2010-2011

Higher rates of hospitalization in ≥ 65 years than in 2011-2012

22% of specimens tested were positive with the virus peaking in February 2011

74% of positive specimens were Type A and 26% were Type B

Proportion of specimens testing positive was <10% during the week ending April 16, 2011

MMWR 2011;60(21):705-712Slide13

Resistance in 2010 to Antivirals

5,758 influenza viral specimens tested for resistance

All 723 influenza B were sensitive to oseltamivir and zanamivir

2 of 806 Influenza A (H3H2) were resistant to oseltamivir

All 784 influenza A (H3H2) were sensitive to zanamivir

Of the 4,229 influenza A (H1N1) 39 were resistant to oseltamivir; of the 771 testes with zanamivir, all were sensitive

High resistance to adamantanes (amantadine and rimantadine)

MMWR 2011;60(21):705-712Slide14

2010-2011 Pneumonia and Influenza Related Mortality

Percentage of deaths attributable to pneumonia and influenza exceeded the epidemic threshold from January 29, 2011 to April 23, 2011

Peaked at 8.9% week ending February 12, 2011

From October 3, 2010 to May 21, 2011 had 311 lab confirmed influenza-associated deaths were reported to CDC

MMWR 2011;60(21):705-712Slide15

Place of Influenza Vaccination Among Adults US 2010-11 Season

Overall: doctor’s office was the most common place (39.8%), followed by “store” (supermarket or drug store) at 18.4%, and workplace 17.4%

Those 65 and older were most likely (51.5%) to be vaccinated at a doctor’s office than a store (24.3%)

High risk individuals were more likely to get their vaccination in a doctor’s office than those without (49.1% vs 35.7%)

MMWR; 60(23): 781-785

.Slide16

Early Estimates of Cumulative Influenza Vaccination Coverage for 2011-2012

Season

Among adults ≥ 18 years, estimated vaccination coverage was 45.5%, an increase from 41.1% the previous season

Estimated 2011-12 coverage among adults 18-49 years increased by 7 percentage points compared to the 2010-11 season.

Estimated coverage among adults increased with each increase in adult age group. Estimated coverage among adults was highest in adults ≥ 65 years (70.8%) and lowest among adults 18-49 years (35.8%).

Estimated coverage among adults 50 to 64 years or ≥ 65 years did not differ when compared to the same time the previous season

.

March

2012 National Immunization Survey and National Flu Survey - United States, 2011-12 Influenza

Season

http://

www.cdc.gov/flu/professionals/vaccination/nfs-survey-march2012.htm accessed 6/6/12Slide17

Place of Vaccination 2011-12

The most common place of vaccination among

adults

(32.5%)

was

a doctor’s office

These

results are similar to results from the 2010-11 season when 31.6% of adults

were

vaccinated in doctor’s offices.

Other common places of influenza vaccination reported for adults during the 2011-12 season included medically related places besides doctor’s offices (24.7%), pharmacies or stores (19.7%), and workplaces (13.8%).

March

2012 National Immunization Survey and National Flu Survey - United States, 2011-12 Influenza Season http://www.cdc.gov/flu/professionals/vaccination/nfs-survey-march2012.htm accessed 6/6/12Slide18

Pneumococcal disease

Pneumococcal disease most often occurs in older people as well as in people with a predisposing condition (e.g., pulmonary disease,

asplenia

).

Pneumococcal disease most commonly presents as a serious infection in the lungs (pneumonia), blood (bacteremia), or brain (meningitis). The annual U.S. case estimate for invasive pneumococcal disease (bacteremia and/or meningitis) is 40,000.

PPSV is 60–70% effective in preventing serious pneumococcal disease; it does not provide substantial protection against all types of pneumonia (viral and bacterial). It is not a “pneumonia” vaccine.

Pneumococcal

Polysaccharide Vaccination Pocket Guide

: http

://

www.immunize.org/ppvguide/pocketguide.pdf; accessed 6/6/12Slide19

Pneumococcal Polysaccharide (PPSV)

Recommended for people 65 years and older; younger than 65 years with chronic illnesses or other risk factors (cardiac, pulmonary, liver disease, alcoholism, diabetes, cigarette smoking); Those at highest risk including asplenia, immunocompromising condition, chemotherapy, or has received organ or bone marrow transplant

Give 1 dose if history is unknown or unvaccinated

Give a 1 time revaccination to:

Age 65 years and older if 1

st

dose was before age 65 years and more than 5 years ago

Age 19-64 years at high risk of fatal pneumococcal infection and 5 years have elapsed since the 1

st

dose

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide20

Estimated proportion of adults

who received Pneumococcal

vaccination 2010

19–64

yrs

, high

risk 18.5

≥65

yrs

59.7

Healthy People 2020 goals call for 90 % of the n

on-institutionalized

adults aged 65 years and

older and 60% of non-institutionalized

high-risk adults aged 18 to 64

years to

be

immunized.

Neither overall coverage nor coverage for any specific age or racial/ethnic group differed significantly from 2009 coverage.

National

Health Interview Survey, United States,

2010-MMWR February

3, 2012 / 61(04);

66-72 accessed 6/6/12Slide21

Case Study 2

A 70 yo male comes into the pharmacy to be immunized for influenza and pneumococcal. He had his last flu shot last year and pneumococcal when he was 60yo.

He asks about the nasal flu vaccine. Is he a candidate? Why or why not?

He asks about the “high dose” flu vaccine. Is he a candidate? Why or why not?

Should he get his PPSV today? Why or why not?Slide22

Herpes Zoster (Shingles) – Give Subcutaneous Injection

For people age 60 years and older

Give 1 time dose if unvaccinated, regardless of history of shingles or chickenpox

If giving 2 or more live vaccines at same time (MMR, Zoster, Yellow fever), should be given on the same day or must be separate by 28 days

Contraindications

Previous anaphylactic reaction to any component of vaccine

Primary cellular or acquired immunodeficiency

Pregnancy

Precautions

Moderate or severe acute illness

Receipt of antivirals 24 hours before vaccination; if possible, delay resuming antivirals for 14 days after vaccination

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide23

Tetanus

Comes as tetanus-diphtheria (Td), tetanus-diphtheria-pertussis (Tdap), or tetanus (TT)

Give intramuscular

All who do not have written documentation of a primary series of at least 3 doses of tetanus and diphtheria

Booster of Td or Tdap may be needed for wound management

In pregnancy, give Td or Tdap if indicated in 2

nd

or 3

rd

trimester. If not given during pregnancy, give Tdap immediate postpartum period

Tdap ONLY:

Adults <65 years who have not already had Tdap

Adults of any agent in close contact with infants < 12 months who have not had a dose of Tdap

Healthcare personnel of all ages

Adults ≥ 65 years without a risk factor may also be vaccinated with Tdap

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide24

Tetanus (cont.)

Schedule

Those unvaccinated or behind, complete the primary Td series (spaced at 0, 1-2months, 6-12 month intervals); substitute a one-time dose of Tdap for one of the doses in the series, preferably the first

Give Td booster every 10 years after primary series has been completed

Tdap can be given regardless of interval since previous Td

Contraindications

Previous anaphylactic reaction to vaccine or components

For Tdap only, history of encephalopathy, not attributable to an identifiable cause, within 7 days following DTP/DTaP

Precautions

Moderate and severe acute illness

Guillian-Barre syndrome within 6 weeks following previous dose of tetanus toxoid containing vaccine

Progressive or unstable neurologic disorder, uncontrolled seizures, or progressive neuropathy

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide25

Hepatitis A (Hep A)

Give Intramuscularly

All who want protection from Hep A and those who work or travel anywhere EXCEPT U.S., Western Europe, New Zealand, Australia, Canada, and Japan

Those with chronic liver disease; injecting & non-injecting drug users; men having sex with men; those getting clotting concentrates; those who work in labs with Hep A; some food handlers

People with close contact with an international adoptee from a country of high or intermediate endemicity during the first 60 days following the adoptee’s arrival in the US

Adults age 40 years or younger with recent (within 2 weeks) exposure to Hep A. For older people (<40years), with recent (within 2 weeks) exposure to Hep A immune globulin is preferred over the Hep A Vaccine

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide26

Hepatitis A (Hep A) cont.

Give 2 doses; minimum interval between doses 1 and 2 is six months

If 2

nd

dose is delayed, don’t repeat the first dose, just give the second dose.

Contraindications:

Previous anaphylactic reaction to this vaccine or to any of its components.

Precautions:

Moderate or severe acute illness

Weigh risk versus benefit in pregnancy

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide27

Hep A and Hep B Combination (Twinrix®)

For 18 years and older

3 doses on 0,1, and 6 month schedule

At least 4 weeks between dose 1 and 2 and 5 months between dose 2 and 3

OR

Alternative schedule: 0, 7day, 21-30 day, and a booster at 12 months

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide28

Hep B

Give intramuscularly

All who want to be protected against Hep B

High risk: household contacts, sex partners, injecting drug users, those not in long term mutually monogamous relationships, men having sex with men, people with HIV, persons seeking STD evaluation or treatment, hemodialysis patients, healthcare personnel and public safety workers, inmates at long term correction facilities, chronic liver disease and certain international travel

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide29

Hep B (cont.)

3 doses on a 0, 1, 6 month schedule

At least 4 weeks between dose 1 and 2, at least eight weeks between doses 2 and 3, at least sixteen weeks between doses 1 and 3

If patients fall behind in schedule, do not start over just pick up where left off

Contraindications: previous anaphylactic reaction to this vaccine or any components

Precautions: Moderate or severe acute illness

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at www.immunize.orgSlide30

Case study 3

A 70yo patient comes into the pharmacy. She is interested in getting her flu shot, pneumococcal vaccine, and anything else she “needs” before she goes to Arizona to help take care of her new twin granddaughters who are 6 weeks old.

What other information do you need to know?

What vaccinations does she need?

What could the pharmacist give her today?Slide31

References

Needle Tips from the Immunization Action Coalition Volume 21 Number 3 July 2011 available at

www.immunize.org

Final state-level influenza vaccination coverage estimates for the 2010–11 season–United States, National Immunization Survey and Behavioral Risk Factor Surveillance System, August 2010 through May 2011 available at

http://www.cdc.gov/flu/professionals/vaccination/coverage_1011estimates.ht

m

MMWR 2011;60(21):705-712

MMWR 2011; 60(23): 781-785.

MMWR 2011:60(33):1128-1132.

Questions & Answers Fluzone High–Dose Seasonal Influenza Vaccine available at

http://www.cdc.gov/flu/protect/vaccine/qa_fluzone.htm

Intradermal Influenza (Flu) Vaccination available at

http://www.cdc.gov/flu/protect/vaccine/qa_intradermal-vaccine.htm

Vaccines, Blood and Biologics FDA Updated Communication on Use of Jet Injectors with Influenza Vaccines. Available at

http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm

accessed on October 26, 2011.